Apaziquone

Drug Profile

Apaziquone

Alternative Names: EO 9; EOquin; Neoquin; NOR 701; NSC 382456; Qapzola

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Spectrum Pharmaceuticals
  • Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
  • Class Aziridines; Cytostatic antibiotics; Indolequinones
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bladder cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer

Most Recent Events

  • 12 Dec 2016 Spectrum Pharmaceuticals terminates a phase III trial in Bladder cancer (non-invasive disease) in USA and Canada due to business reasons (NCT01410565)
  • 14 Sep 2016 The Oncologic Drugs Advisory Committee (ODAC) does not recommends approval of apaziquone for Bladder cancer in USA
  • 06 May 2016 Updated efficacy and adverse events data from two phase III trials in Bladder Cancer presented at the 111th Annual Meeting of the American Urological Association (AUA 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top